IGF-I (24-41) (TFA) is amino acids 24 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
IGF-I (24-41) TFA is a synthetic peptide fragment derived from the central region of insulin-like growth factor I, incorporating residues 24 to 41 and presented as its trifluoroacetate salt. As a defined peptide sequence, it encompasses a segment of the IGF-I protein that is involved in modulating cellular signaling, growth, and metabolic processes. Its well-characterized structure and manageable length make it a valuable molecular tool for dissecting the functional domains of IGF-I, facilitating mechanistic studies in cellular and molecular biology. Researchers employ this peptide to probe the effects of IGF-I subregions, investigate receptor binding specificity, and elucidate downstream signaling pathways, underpinning its significance in both fundamental and applied bioscience.
Peptide structure-function analysis: IGF-I (24-41) TFA is widely used in investigations aiming to map the functional domains of the full-length IGF-I protein. By isolating and studying this specific segment, researchers can delineate the contributions of central residues to receptor interaction and biological activity. Such studies are instrumental in identifying minimal motifs required for bioactivity, advancing the understanding of how IGF-I mediates its diverse cellular effects. The ability to manipulate and test discrete peptide regions provides a mechanistic basis for rational design in protein engineering and therapeutic research.
Receptor binding studies: The peptide serves as a precise tool for examining the interaction between IGF-I and its cognate receptors, including the IGF-I receptor and related binding proteins. By employing IGF-I (24-41) in ligand-binding assays or competitive inhibition experiments, scientists can assess the affinity and specificity of this fragment compared to the full-length protein. These investigations help clarify the structural determinants of receptor engagement, support the development of novel receptor modulators, and contribute to the broader field of growth factor signaling research.
Cell signaling pathway elucidation: In cell-based assays, IGF-I (24-41) TFA is utilized to study the activation or modulation of intracellular signaling cascades downstream of IGF-I receptor engagement. Researchers can monitor key events such as phosphorylation of signaling intermediates, gene expression changes, or cellular proliferation in response to peptide exposure. This approach provides insight into the functional consequences of partial IGF-I sequences, enabling the dissection of pathway specificity and the identification of context-dependent signaling outcomes.
Peptide synthesis and assay development: The defined sequence and manageable length of IGF-I (24-41) make it a practical standard or reference in peptide synthesis protocols and analytical method development. It is frequently used to optimize solid-phase peptide synthesis conditions, calibrate chromatographic systems, and validate detection assays such as mass spectrometry or immunoassays. The peptide's stability and well-characterized properties support its role as a benchmark in quality control and methodological studies within peptide chemistry laboratories.
Protein-protein interaction modeling: IGF-I (24-41) TFA is also employed in structural biology and computational modeling to simulate and predict interactions between IGF-I subdomains and binding partners. By integrating experimental data with in silico approaches, scientists can explore the conformational dynamics of the peptide, identify potential contact sites, and generate hypotheses for mutagenesis or inhibitor design. This application enhances the mechanistic understanding of IGF-I-mediated signaling and informs the rational development of molecular probes or modulators targeting the IGF axis.
1. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
4. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More